Work

Allometric scaling of preclinical pharmacokinetic and toxicokinetic parameters to predict clinical pharmacokinetics of BXQ-350 saposin C protein-phosphatidylserine nanovesicles.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.e14537

Authors: Charles A Cruze, Olivier Rixe, John Charles Morris, Vinay K. Puduvalli, John L. Villano, Trisha Michel Wise-Draper, Angela N. Johnson, Robert Wesolowski, Gary A. Thompson

Institutions: Bexion Pharmaceuticals (United States), UNM Comprehensive Cancer Center, University of Cincinnati, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University of Kentucky, Markey Cancer Center, Clinical Trial and Consulting, The Ohio State University, Chester County Historical Society

Language: English

Topic: Pharmaceutical studies and practices

Subfield: Pediatrics, Perinatology and Child Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891756788

Cites:

Cited by:

Related to: 10